ATC code L02
Pharmaceutical drug classification
| ATC code L: Antineoplastic and immunomodulating agents |
|---|
|
| Other ATC codes |
ATC code L02 Endocrine therapy is a therapeutic subgroup of the Anatomical Therapeutic Chemical Classification System, a system of alphanumeric codes developed by the World Health Organization (WHO) for the classification of drugs and other medical products.[1][2][3] Subgroup L02 is part of the anatomical group L Antineoplastic and immunomodulating agents.[4]
Codes for veterinary use (ATCvet codes) can be created by placing the letter Q in front of the human ATC code: for example, QL02.[5]
National issues of the ATC classification may include additional codes not present in this list, which follows the WHO version.
L02AA Estrogens
- L02AA01 Diethylstilbestrol
- L02AA02 Polyestradiol phosphate
- L02AA03 Ethinylestradiol
- L02AA04 Fosfestrol
L02AB Progestogens
- L02AB01 Megestrol
- L02AB02 Medroxyprogesterone
- L02AB03 Gestonorone
L02AE Gonadotropin-releasing hormone analogues
- L02AE01 Buserelin
- L02AE02 Leuprorelin
- L02AE03 Goserelin
- L02AE04 Triptorelin
- L02AE05 Histrelin
- L02AE51 Leuprorelin and bicalutamide
L02AX Other hormones
L02BA Anti-estrogens
- L02BA01 Tamoxifen
- L02BA02 Toremifene
- L02BA03 Fulvestrant
- L02BA04 Elacestrant
L02BB Anti-androgens
- L02BB01 Flutamide
- L02BB02 Nilutamide
- L02BB03 Bicalutamide
- L02BB04 Enzalutamide
- L02BB05 Apalutamide
- L02BB06 Darolutamide
L02BG Aromatase inhibitors
- L02BG01 Aminogluthetimide
- L02BG02 Formestane
- L02BG03 Anastrozole
- L02BG04 Letrozole
- L02BG05 Vorozole
- L02BG06 Exemestane
- L02BX01 Abarelix
- L02BX02 Degarelix
- L02BX03 Abiraterone
- L02BX04 Relugolix
- L02BX53 Abiraterone and prednisolone
References
- ^ "ATC (Anatomical Therapeutic Chemical Classification System) – Synopsis". National Institutes of Health. Retrieved 1 February 2020.
- ^ World Health Organization. "Anatomical Therapeutic Chemical (ATC) Classification". World Health Organization. Retrieved 3 January 2022.
- ^ "Structure and principles". WHO Collaborating Centre for Drug Statistics Methodology. 15 February 2018. Retrieved 3 January 2022.
- ^ "ATC/DDD Index 2022: code L02". WHO Collaborating Centre for Drug Statistics Methodology.
- ^ "ATCvet Index 2022: code QL02". WHO Collaborating Centre for Drug Statistics Methodology.
- v
- t
- e
(incl. AASTooltip anabolic–androgenic steroid)
| ARTooltip Androgen receptor antagonists | |||||
|---|---|---|---|---|---|
| Steroidogenesis inhibitors |
| ||||
| Antigonadotropins |
| ||||
| Others |
|
- #WHO-EM
- ‡Withdrawn from market
- Clinical trials:
- †Phase III
- §Never to phase III
- See also
- Androgen receptor modulators
- Estrogens and antiestrogens
- Progestogens and antiprogestogens
- List of androgens/anabolic steroids
